NanoVibronix, Inc. (NAOV)
NASDAQ: NAOV · Real-Time Price · USD
0.706
+0.039 (5.77%)
At close: Nov 22, 2024, 4:00 PM
0.671
-0.035 (-5.01%)
After-hours: Nov 22, 2024, 4:18 PM EST
NanoVibronix Revenue
NanoVibronix had revenue of $376.00K in the quarter ending September 30, 2024, a decrease of -17.90%. This brings the company's revenue in the last twelve months to $3.29M, up 227.79% year-over-year. In the year 2023, NanoVibronix had annual revenue of $2.28M with 203.59% growth.
Revenue (ttm)
$3.29M
Revenue Growth
+227.79%
P/S Ratio
0.54
Revenue / Employee
$205,688
Employees
16
Market Cap
2.65M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2.28M | 1.53M | 203.59% |
Dec 31, 2022 | 752.00K | -943.00K | -55.63% |
Dec 31, 2021 | 1.70M | 1.07M | 172.07% |
Dec 31, 2020 | 623.00K | 93.00K | 17.55% |
Dec 31, 2019 | 530.00K | 212.00K | 66.67% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Venus Concept | 67.20M |
Xylo Technologies | 57.64M |
Scorpius Holdings | 10.04M |
Avinger | 7.26M |
Biodexa Pharmaceuticals | 104.90K |
HeartSciences | 18.60K |
NAOV News
- 10 days ago - NanoVibronix Provides Business Update - Business Wire
- 6 weeks ago - NanoVibronix Takes Next Step to Partner with Specialist Urology Company to Expand Sales of UroShield in Germany - Business Wire
- 2 months ago - NanoVibronix Signs Letter of Intent with Potential New Distributor - Business Wire
- 3 months ago - NanoVibronix Highlights Second Quarter Revenue Growth and Narrowing of Loss from Operations in Letter to Stockholders - Business Wire
- 6 months ago - NanoVibronix Announces Commencement of UroShield Clinical Study at the University of Michigan - Business Wire
- 6 months ago - NanoVibronix Issues Letter to Stockholders - Business Wire
- 6 months ago - NanoVibronix Announces Distribution Agreement with VA Supplier CB Medical for the Distribution of UroShield - Business Wire
- 7 months ago - NanoVibronix Announces PainShield Will Be Included in Department of Veteran Affairs' FSS Contract Award - Business Wire